Tropomyosin Receptor Kinase (TRK): Another Promising Target in Metastatic Colorectal Cancer* Report on the clinical relevance of the TPM3-NTRK1 fusion in CRC* Demonstration of in vitro/in vivo antitumor activity of NMS-P626, a TrkA inhibitor with activity against TPM3-TrkA* Identification of ...
Neurotrophic tyrosine receptor kinase gene fusions are oncogenic drivers of various solid tumors. Larotrectinib is a highly selective tropomyosin receptor kinase (TRK) inhibitor approved for patients with TRK fusion cancer on the basis of single-arm trials. This study was a matched comparative ...
TRK tropomyosin receptor kinase VCL vinculin VEGFR2 vascular endothelial growth factor receptor 2 1. Introduction Tropomyosin receptor kinases A, B and C (TRKA, TRKB and TRKC), which belong to the cell surface receptor tyrosine kinase (RTK) family, are encoded by the neurotrophic receptor tyrosine...
Sherri Gordon, Health, 7 Sep. 2024 In February, for example, Hyman and co-authors reported in The New England Journal of Medicine that a drug aimed at genes known as tropomyosin receptor kinase (TRK) fusions works for many tumor types. Jocelyn Kaiser, Science | AAAS, 24 Apr. 2018 Word...
Inflammation is an essential component of arthritis pain. Nerve growth factor (NGF) plays a key role in acute and chronic pain states especially those associated with inflammation. NGF acts through tropomyosin-receptor-kinase A (TrkA). NGF blockade has r
Tropomyosin-receptor kinase fused gene (TFG) is located in ER exit sites and participates in COPII-coated vesicle formation along with many scaffold proteins, such as Sec. 13 and Sec. 16. In this study, we investigated the putative role of TFG in lipid production in sebocytes using an ...
Clinical trials have reported the efficacy of tropomyosin receptor kinase (TRK) inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors. The accumulated evidence of tumor-agnostic agent has made since TRK inhibitors were approved and used in clinical pra...
667P Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer Author links open overlay panelD.S. Hong 1, R-H. Xu 2, R.S. McDermott 3, L. Shen 4, M.P. Dierselhuis 5, F. Doz 6, M. Tahara ...
The trk oncogene is a human transforming gene generated by the fusion of tropomyosin gene sequences to a truncated tyrosine kinase receptor gene1. We have now characterized the normal tropomyosin gene from which the trk oncogene is derived. At least two
The invention relates to monoclonal antibodies directed to a particular part of tropomyosin-related kinase B receptor (TrkB) and hybridoma cell lines producing these. Fragments of t